Critical Risk Analysis: 50-Year-Old with 20-Day Starvation + Catatonia + Multi-Organ Compromise

1. REFEEDING SYNDROME (IMMINENT, HIGHEST PRIORITY)

• Severe hypophosphatemia - the hallmark. Phosphate is already depleted after 20 days; the insulin-driven intracellular shift can drop serum phosphate precipitously.
• Worsening of hypokalemia (already at 2.3) - insulin further drives K⁺ into cells
• Hypomagnesemia - compounds cardiac arrhythmia risk
• Hypocalcemia - tetany, seizures

• Cardiac arrhythmias and sudden cardiac arrest
• Respiratory failure (diaphragm weakness from hypophosphatemia)
• Confusion, seizures, coma
• Haemolytic anaemia
• Ileus

"Refeeding syndrome is a potentially lethal condition...symptoms from electrolyte abnormalities include cardiac arrhythmias, confusion, respiratory failure, and even death." - Schwartz's Principles of Surgery, 11e

"Underlying electrolyte and volume deficits should be corrected. Additionally, thiamine should be administered before the initiation of feeding. Caloric repletion should be instituted slowly." - Schwartz's, p. 126

2. SEVERE HYPOKALEMIA (K⁺ = 2.3 mEq/L) + ACUTE KIDNEY INJURY (Creatinine = 3)

Risks from K⁺ = 2.3:

• Ventricular arrhythmias (VT, VF, torsades de pointes) - ECG monitoring is mandatory
• Diaphragmatic and skeletal muscle weakness - worsens risk of respiratory failure
• Rhabdomyolysis (already suspected given prolonged immobility in catatonia + starvation)
• Further aggravation by diazepam-induced sedation (reduced respiratory drive + muscle weakness = hypoventilation)

Risk from Creatinine = 3 (AKI):

• Potassium correction must be done very cautiously. In AKI, the kidneys cannot excrete excess potassium. However, at K⁺ = 2.3, replacement is needed - but over-replacement risks fatal hyperkalemia as renal function fluctuates.
• AKI in this context is likely pre-renal/intrinsic due to volume depletion from 20 days of starvation, muscle breakdown (rhabdomyolysis), and possibly RL fluids insufficient for the degree of depletion.
• RL (Ringer's Lactate) contains 4 mEq/L of K⁺ - appropriate over DNS, but rate and total load need monitoring given the AKI.
• Fluid overload risk: the bilateral leg and hand oedema suggests third-spacing or hypoalbuminaemia from starvation malnutrition, not volume excess per se - yet aggressive fluids in AKI can worsen pulmonary oedema.

"Oliguric renal failure requires close monitoring of serum potassium levels...should be instituted early, including consideration of early hemodialysis." - Schwartz's, p. 126

3. DIAZEPAM RISKS IN THIS CLINICAL CONTEXT

Preferred agent concern:

• The preferred benzodiazepine for catatonia per evidence is lorazepam (not diazepam), due to its shorter half-life and lack of active metabolites.
• Diazepam has a very long half-life (20-100 hours) and its active metabolite desmethyldiazepam (half-life 36-200 hours) accumulates.

In the context of AKI and starvation:

• Protein binding is reduced (hypoalbuminaemia from starvation) → higher free fraction → more sedation than expected per dose
• Drug accumulation with 6-hourly dosing: by day 3-4, plasma levels may be 3-4x the initial level
• One case of interstitial nephritis with diazepam in chronic renal failure is documented (Maudsley Prescribing Guidelines, 15e)

Respiratory risk:

• The patient already has muscle weakness from starvation + hypokalemia
• Diazepam causes central respiratory depression
• Combined with these factors: high risk of respiratory failure and need for intubation

IV Propylene glycol (PGS) toxicity:

• Diazepam injection contains propylene glycol as solvent
• With repeated high-dose IV dosing (every 6 hours), propylene glycol accumulates especially in renal failure
• Causes: metabolic acidosis (raised anion gap), renal tubular toxicity, worsening AKI

"Benzodiazepine monotherapy is the treatment of choice for stupor occurring in the context of affective and conversion disorders. There is most clinical experience with lorazepam." - Maudsley Prescribing Guidelines, 15e, p. 179

4. OEDEMA: CAUSE AND RISK

1. Hypoalbuminaemia from 20 days starvation (main cause) - third-spacing of fluids
2. Renal retention from AKI (creatinine = 3)
3. Possibly early cardiac decompensation if the electrolyte abnormalities are causing subclinical cardiac dysfunction

• They worsen hypokalemia (K⁺ already at 2.3)
• They can worsen AKI (further reduce renal perfusion)
• Use only if frank pulmonary oedema develops

5. CATATONIA-SPECIFIC RISKS

• Aspiration pneumonia - the catatonic posturing, negativism, and inability to eat/swallow places the airway at risk. The catheterisation confirms loss of voluntary function. With current position maintenance, secretions pool.
• DVT/PE - 20 days of immobility + dehydration = very high risk of deep venous thrombosis. Pulmonary embolism in a compromised patient could be fatal.
• Pressure ulcers - prolonged posturing damages skin over bony prominences.
• Malignant catatonia - if hyperthermia, autonomic instability, or elevated CK develops, this escalates to a neuroleptic malignant syndrome-like emergency requiring ICU care, and benzodiazepines alone may be insufficient.
• Worsening of AKI from rhabdomyolysis - sustained muscle rigidity/posturing causes myoglobinuria, which directly damages renal tubules.

6. DNS (Dextrose Normal Saline) - SPECIFIC CONCERNS

Summary Priority Action List

When is Catatonia Considered Not Responding to Benzodiazepines?

Step 1: The Lorazepam Challenge Test (Diagnosing AND Predicting Response)

• Give lorazepam 1-2 mg IV (0.5-1 mg in elderly/children)
• Observe for ≥50% improvement in catatonia symptoms within 5 minutes
• If no change at 5 minutes: give an additional 1-2 mg IV
• Failure to respond to this challenge does not immediately mean treatment-resistant - it may mean the diagnosis needs reconsideration (e.g., NMS, autoimmune encephalitis, malignant catatonia)

"The diagnosis can be confirmed by improvement after a challenge dose of a benzodiazepine (typically 1 to 2 mg of lorazepam IV). If no change in symptoms is noted within 5 minutes, an additional 1 to 2 mg of lorazepam can be given." - Goldman-Cecil Medicine

Note for your patient: Diazepam 5 mg IV is being used. Diazepam is effective but at 5x the lorazepam dose (so 5 mg diazepam ≈ 1 mg lorazepam). The current 5 mg 6-hourly dose is on the lower end of the effective range.

Step 2: What Constitutes an "Adequate Trial" Before Declaring Non-Response?

Phase 1 - Standard Dose: 1-2 days at lorazepam up to 4 mg/day

• Start with lorazepam 2 mg IM/IV
• Give a further 2 mg if no effect after 3 hours
• Use IM route for subsequent doses in non-cooperative patients
• If no response after 1-2 days → move to Phase 2

Phase 2 - High Dose: 1-2 days at lorazepam 8-24 mg/day (up to 30 mg/day in some protocols)

• Escalate to 6-16 mg/day in divided doses, sometimes as high as 30 mg/day
• IV lorazepam or diazepam infusion can be used here
• One protocol: IV infusion of 10 mg diazepam in 500 mL normal saline at 1.25 mg/hr until catatonia remits
• If no response after another 1-2 days → declare benzodiazepine non-response

"Many patients will respond to standard doses (up to 4 mg/day) but repeated and higher doses (between 8 and 24 mg per day) may be needed." - Maudsley Prescribing Guidelines, 15e

"The dose is further increased to 6 to 16 mg/day, and sometimes as much as 30 mg/day." - Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Step 3: The Treatment Algorithm (Maudsley Prescribing Guidelines, 15e)

• No response after 1-2 days at standard dose → escalate to high dose (8-24 mg/day)
• No response after further 1-2 days at high dose → proceed to ECT
• In psychotic illness: first rule out NMS, consider SGA (clozapine/olanzapine), then ECT if still no response

"Do not wait to give ECT if there is significant danger to life."

Step 4: Specific Contexts That Change the Timeline

"Several studies suggest a more robust response to lorazepam is more likely with a shorter duration of catatonia and waxy flexibility. Factors predicting poorer response include passivity, mutism, auditory hallucinations, marked retardation complicating schizophrenia." - Kaplan & Sadock's Comprehensive Textbook

Step 5: What to Do When Non-Response is Declared

1. ECT (Electroconvulsive Therapy) - the most evidence-based next step. Highest response rates in all forms of catatonia, including malignant. A 2024 systematic review reinforced ECT as effective and suggested it may be considered first-line in certain cases (Maudsley, 15e). In malignant catatonia: liberal stimulus dosing for well-generalised seizures.
2. Memantine 10 mg/day or Amantadine 100 mg/day (glutamate antagonists) - may be added alongside benzodiazepines to allow dose reduction while maintaining effect
3. Second-generation antipsychotics (if psychotic etiology, NMS ruled out): clozapine, olanzapine, aripiprazole - with caution (can worsen catatonia or precipitate NMS)
4. rTMS / tDCS - emerging evidence, may be considered when ECT is unavailable or refused

Applied to Your Current Patient

• If there is no meaningful improvement in 1-2 more days, this qualifies as non-response to standard dosing
• The next step would be dose escalation (increase diazepam to 10-15 mg 6-hourly, or switch to lorazepam 4-6 mg/day)
• However, given this patient's AKI (creatinine = 3), hypoalbuminaemia, respiratory risk, and propylene glycol toxicity from IV diazepam - ECT consultation should be initiated now in parallel with continued benzodiazepine therapy, rather than waiting for full non-response
• The note from Maudsley is especially relevant here: "Do not wait to give ECT if there is significant danger to life" - and this patient's overall condition qualifies